Caseware UK (AP4) 2024.0.164 2024.0.164 2026-03-312026-03-31truetruetruetruefalse2025-04-01true44truefalse 08449728 2025-04-01 2026-03-31 08449728 2024-04-01 2025-03-31 08449728 2026-03-31 08449728 2025-03-31 08449728 2024-04-01 08449728 c:CompanySecretary1 2025-04-01 2026-03-31 08449728 c:Director1 2025-04-01 2026-03-31 08449728 c:Director2 2025-04-01 2026-03-31 08449728 c:Director3 2025-04-01 2026-03-31 08449728 c:Director4 2025-04-01 2026-03-31 08449728 c:Director4 2026-03-31 08449728 c:RegisteredOffice 2025-04-01 2026-03-31 08449728 d:CurrentFinancialInstruments 2026-03-31 08449728 d:CurrentFinancialInstruments 2025-03-31 08449728 d:CurrentFinancialInstruments d:WithinOneYear 2026-03-31 08449728 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 08449728 d:ShareCapital 2026-03-31 08449728 d:ShareCapital 2025-03-31 08449728 d:ShareCapital 2024-04-01 08449728 d:RetainedEarningsAccumulatedLosses 2025-04-01 2026-03-31 08449728 d:RetainedEarningsAccumulatedLosses 2026-03-31 08449728 d:RetainedEarningsAccumulatedLosses 2025-03-31 08449728 d:RetainedEarningsAccumulatedLosses 2024-04-01 08449728 c:OrdinaryShareClass1 2025-04-01 2026-03-31 08449728 c:OrdinaryShareClass1 2026-03-31 08449728 c:OrdinaryShareClass1 2025-03-31 08449728 c:EntityHasNeverTraded 2025-04-01 2026-03-31 08449728 c:FRS102 2025-04-01 2026-03-31 08449728 c:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 08449728 c:FullAccounts 2025-04-01 2026-03-31 08449728 c:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 08449728 d:Subsidiary1 2025-04-01 2026-03-31 08449728 d:Subsidiary1 1 2025-04-01 2026-03-31 08449728 d:Subsidiary2 2025-04-01 2026-03-31 08449728 d:Subsidiary2 1 2025-04-01 2026-03-31 08449728 d:Subsidiary3 2025-04-01 2026-03-31 08449728 d:Subsidiary3 1 2025-04-01 2026-03-31 08449728 d:Subsidiary4 2025-04-01 2026-03-31 08449728 d:Subsidiary4 1 2025-04-01 2026-03-31 08449728 d:Subsidiary5 2025-04-01 2026-03-31 08449728 d:Subsidiary5 1 2025-04-01 2026-03-31 08449728 d:Subsidiary6 2025-04-01 2026-03-31 08449728 d:Subsidiary6 1 2025-04-01 2026-03-31 08449728 d:Subsidiary7 2025-04-01 2026-03-31 08449728 d:Subsidiary7 1 2025-04-01 2026-03-31 08449728 d:Subsidiary8 2025-04-01 2026-03-31 08449728 d:Subsidiary8 1 2025-04-01 2026-03-31 08449728 d:Subsidiary9 2025-04-01 2026-03-31 08449728 d:Subsidiary9 1 2025-04-01 2026-03-31 08449728 d:Subsidiary10 2025-04-01 2026-03-31 08449728 d:Subsidiary10 1 2025-04-01 2026-03-31 08449728 d:Subsidiary11 2025-04-01 2026-03-31 08449728 d:Subsidiary11 1 2025-04-01 2026-03-31 08449728 d:Subsidiary12 2025-04-01 2026-03-31 08449728 d:Subsidiary12 1 2025-04-01 2026-03-31 08449728 d:Subsidiary13 2025-04-01 2026-03-31 08449728 d:Subsidiary13 1 2025-04-01 2026-03-31 08449728 d:Subsidiary14 2025-04-01 2026-03-31 08449728 d:Subsidiary14 1 2025-04-01 2026-03-31 08449728 d:Subsidiary15 2025-04-01 2026-03-31 08449728 d:Subsidiary15 1 2025-04-01 2026-03-31 08449728 d:Subsidiary16 2025-04-01 2026-03-31 08449728 d:Subsidiary16 1 2025-04-01 2026-03-31 08449728 d:Subsidiary17 2025-04-01 2026-03-31 08449728 d:Subsidiary17 1 2025-04-01 2026-03-31 08449728 d:Subsidiary18 2025-04-01 2026-03-31 08449728 d:Subsidiary18 1 2025-04-01 2026-03-31 08449728 d:Subsidiary19 2025-04-01 2026-03-31 08449728 d:Subsidiary19 1 2025-04-01 2026-03-31 08449728 d:Subsidiary20 2025-04-01 2026-03-31 08449728 d:Subsidiary20 1 2025-04-01 2026-03-31 08449728 d:Subsidiary21 2025-04-01 2026-03-31 08449728 d:Subsidiary21 1 2025-04-01 2026-03-31 08449728 d:Subsidiary22 2025-04-01 2026-03-31 08449728 d:Subsidiary22 1 2025-04-01 2026-03-31 08449728 d:Subsidiary23 2025-04-01 2026-03-31 08449728 d:Subsidiary23 1 2025-04-01 2026-03-31 08449728 d:Subsidiary24 2025-04-01 2026-03-31 08449728 d:Subsidiary24 1 2025-04-01 2026-03-31 08449728 d:Subsidiary25 2025-04-01 2026-03-31 08449728 d:Subsidiary25 1 2025-04-01 2026-03-31 08449728 d:Subsidiary26 2025-04-01 2026-03-31 08449728 d:Subsidiary26 1 2025-04-01 2026-03-31 08449728 d:Subsidiary27 2025-04-01 2026-03-31 08449728 d:Subsidiary27 1 2025-04-01 2026-03-31 08449728 d:Subsidiary28 2025-04-01 2026-03-31 08449728 d:Subsidiary28 1 2025-04-01 2026-03-31 08449728 d:Subsidiary29 2025-04-01 2026-03-31 08449728 d:Subsidiary29 1 2025-04-01 2026-03-31 08449728 d:Subsidiary30 2025-04-01 2026-03-31 08449728 d:Subsidiary30 1 2025-04-01 2026-03-31 08449728 6 2025-04-01 2026-03-31 08449728 e:PoundSterling 2025-04-01 2026-03-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 08449728









WILLOWBROOK HEALTHCARE GROUP LIMITED







UNAUDITED

ANNUAL REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
COMPANY INFORMATION


Directors
L C Colt 
K S B Olsson 
D A Reuben 
J M B Strowbridge (resigned 22 October 2025)




Company secretary
M R Molsom



Registered number
08449728



Registered office
3 Cygnet Drive
Swan Valley

Northampton

United Kingdom

NN4 9BS




Accountants
Adler Shine LLP
Chartered Accountants

Aston House

Cornwall Avenue

London

N3 1LF





 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 

CONTENTS



Page
Strategic Report
 
1 - 2
Directors' Report
 
3 - 4
Statement of Comprehensive Income
 
5
Balance Sheet
 
6
Statement of Changes in Equity
 
7
Notes to the Financial Statements
 
8 - 15


 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
STRATEGIC REPORT
FOR THE YEAR ENDED 31 MARCH 2026

Introduction
 
The directors present the strategic report for the year ended 31 March 2026.

Business review
 
The Company acts as an interim holding company. The Company has taken exemption from preparing consoldiated financial statements for the Group; these financial statements therefore present the results of the Company only. Subsidiaries are operated as residential care for the elderly and disabled during the year.
Due to the limited activity within the Company, a detailed business review for the group, including an analysis of principal risks and uncertainties, review of key performance indicators and engagement with employees and suppliers can be found in the strategic report of Avery Healthcare Holdings Limited, a group company registered in England and Wales. The consolidated financial statements of Avery Healthcare Holdings Limited can be obtained from Companies House.

Principal risks and uncertainties
 
The Company is a subsidiary of Avery Healthcare Group Limited and is managed on a unified basis as part of the Avery Healthcare Group. The principal risks faced by the Company reflect those of the Avery Healthcare Group in delivering its strategic priorities for the forthcoming year. These are listed below:
• Continued assessment of the long term care sector and the potential changes on the horizon;
• Review of government policy and the impact on the care sector of proposed changes in either social
  economic terms or direct government focus. Respond to potential changes in the general political view of
  the privately provided care sector;
• Review of the housing market and pensions, enabling an assessment of service user’s ability to pay for
  care services.
Objectives
• To establish and integrate care homes within the Avery Healthcare Holdings Group. They will all be of thef
 highest quality from both an environmental and care delivery perspective;
• To recruit and provide training to staff of a similarly high calibre;
• Continue to evolve and use our quality assurance system to assist in this aim of providing high quality 
 care to the vulnerable elderly;
• Continuous expenditure on the environment and fabric of the buildings. Continued recognition of the
  importance of this to the residents of our facilities;
• To achieve above industry average outcomes from reviews and inspections undertaken by sector
  regulators; and
• To achieve a financial performance in line with budget and in excess of sector norms.
How we will achieve this
• Providing a career path for all our staff;
• Providing the training and support to teach staff the art of caring;
• Complying with all regulatory requirements; and
• Providing better care than our competitors.
How we will assess our performance
• Close supervision of home managers by high calibre and experienced regional managers;
• Achievable care home budgets; and
• Weekly reporting to care home managers on key performance indicators.
 

Page 1

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 

STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026

Financial key performance indicators
 
The Company monitors the performance of the business using the following:
• Earnings before interest, depreciation, amortisation and tax; 
• Operating cash generation.

Other key performance indicators
 
Management monitor and review financial and non-financial KPIs such as: occupancy rates, average fee rates, agency usage and its Care Quality Commission ratings.


This report was approved by the board and signed on its behalf.



................................................
K S B Olsson
Director

Date: 30 June 2026

Page 2

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2026

The directors present their report and the financial statements for the year ended 31 March 2026.

Directors' responsibilities statement

The directors are responsible for preparing the Strategic Report, the Directors' Report and the financial statements in accordance with applicable law and regulations.
 
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period.

 In preparing these financial statements, the directors are required to:


∙select suitable accounting policies for the Company's financial statements and then apply them consistently;

∙make judgements and accounting estimates that are reasonable and prudent;

∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;

∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Principal activity

The Company is a holding company and has not traded during the period.

Directors

The directors who served during the year were:

L C Colt 
K S B Olsson 
D A Reuben 
J M B Strowbridge (resigned 22 October 2025)

Future developments

The Company continues to drive the same standards and service levels while seeking to continue to grow the business and its offering.

Page 3

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2026

Engagement with suppliers, customers and others

The Company is dormant and, as set-out in the Strategic Report, the Company has taken exemption from preparing consolidated financial statements. 
Details on how the group and the company have fostered relationships with suppliers, customers and others can be found within the section 172 statement in the Strategic Report of Avery Healthcare Holdings Limited, as noted in the company’s Strategic Report.

Post balance sheet events

There have been no significant events affecting the Company since the year end.

This report was approved by the board and signed on its behalf.
 





................................................
K S B Olsson
Director

Date: 30 June 2026

Page 4

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 MARCH 2026

The Company has not traded during the year or the preceding financial year. During these periods, the Company received no income and incurred no expenditure and therefore made neither profit or loss.



  

There were no recognised gains and losses for 2026 or 2025 other than those included in the statement of comprehensive income.

There was no other comprehensive income for 2026 (2025:£NIL).

The notes on pages 8 to 15 form part of these financial statements.

Page 5

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
REGISTERED NUMBER: 08449728

BALANCE SHEET
AS AT 31 MARCH 2026

2026
2025
Note
£
£

Fixed assets
  

Investments
 5 
12,020,700
12,020,700

  
12,020,700
12,020,700

Current assets
  

Debtors: amounts falling due within one year
 6 
4,097,278
4,097,278

  
4,097,278
4,097,278

Creditors: amounts falling due within one year
 7 
(16,017,977)
(16,017,977)

Net current liabilities
  
 
 
(11,920,699)
 
 
(11,920,699)

Total assets less current liabilities
  
100,001
100,001

  

Net assets
  
100,001
100,001


Capital and reserves
  

Called up share capital 
 8 
1
1

Profit and loss account
 9 
100,000
100,000

  
100,001
100,001




For the year ended 31 March 2026 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 


................................................
K S B Olsson
Director

Date: 30 June 2026

The notes on pages 8 to 15 form part of these financial statements.

Page 6

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026


Called up share capital
Profit and loss account
Total equity

£
£
£


At 1 April 2024
1
100,000
100,001



At 1 April 2025
1
100,000
100,001


At 31 March 2026
1
100,000
100,001


The notes on pages 8 to 15 form part of these financial statements.

Page 7

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

1.


General information

Willowbrook Healthcare Group Limited is a private company limited by shares incorporated in England and Wales. The registered office address is 3 Cygnet Drive, Swan Valley, Northampton, NN4 9BS.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The financial statements are prepared in Pounds sterling, which is the functional currency of the Company, rounded to the nearest £1.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the Company's accounting policies (see note 3).

 
2.2

Financial Reporting Standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by the FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":
∙the requirements of Section 7 Statement of Cash Flows;
∙the requirements of Section 3 Financial Statement Presentation paragraph 3.17(d);
∙the requirements of Section 11 Financial Instruments paragraphs 11.42, 11.44 to 11.45, 11.47, 11.48(a)(iii), 11.48(a)(iv), 11.48(b) and 11.48(c);
∙the requirements of Section 12 Other Financial Instruments paragraphs 12.26 to 12.27, 12.29(a), 12.29(b) and 12.29A;
∙the requirements of Section 33 Related Party Disclosures paragraph 33.7.

This information is included in the consolidated financial statements of Avery Healthcare Holdings Limited as at 31 March 2026 and these financial statements may be obtained from Companies House.

 
2.3

Exemption from preparing consolidated financial statements

The Company is a parent company that is also a subsidiary included in the consolidated financial statements of a larger group by a parent undertaking established under the law of any part of the United Kingdom and is therefore exempt from the requirement to prepare consolidated financial statements under section 400 of the Companies Act 2006.

Page 8

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

 
2.4

Going concern

At the time of approving the financial statements, the directors have a reasonable expectation that
the Company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
The group headed by Avery Healthcare Holdings Limited has agreed to continue to provide the Company with the necessary financial support and working capital for at least one year from the date of the approval of these financial statements to allow the Company to meet its liabilities as they fall due. The Company is also subject to cross guaranteed property leasing with other Group undertakings. Detailed information regarding the financial position of the group headed by Avery Healthcare Holdings Limited, its cash flows, liquidity position and borrowing facilities are included in the financial statements of Avery Healthcare Holdings Limited, which can be obtained from Companies House.
The group meets its day-to-day working capital requirements through operating cash flows and debt internal financing. Having reviewed the group's financial forecasts and expected future cash flows, the directors are confident that the group has adequate resources to continue in operational existence for the foreseeable future. Consequently, the directors are confident that the group will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.

 
2.5

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance Sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
 
Page 9

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)


2.7
Financial instruments (continued)


Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Impairment of financial assets

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss. 

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the
Page 10

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)


2.7
Financial instruments (continued)

effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Derecognition of financial instruments

Derecognition of financial assets

Financial assets are derecognised when their contractual right to future cash flow expire, or are settled, or when the Company transfers the asset and substantially all the risks and rewards of ownership to another party. If significant risks and rewards of ownership are retained after the transfer to another party, then the Company will continue to recognise the value of the portion of the risks and rewards retained.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Company's contractual obligations expire or are discharged or cancelled.


3.


Judgements in applying accounting policies and key sources of estimation uncertainty

In the application of the Company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. 
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
Provisions
The directors have considered the requirement for provisions in respect of the recoverability of the value of assets and debts, as well as provisions for liabilities (including accrued expenses) based on reasonable expectations, knowledge of the business and historic trends.
Judgements have been made in relation to the recoverability of debtors and the directors are satisfied that adequate provision is made such that debts stated net of provisions are recoverable.
The directors have considered and concluded that the valuations of provisions are appropriate.


4.


Employees

The company did not have any employees in the year or the preceding financial year.





Page 11

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

5.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 April 2025
12,020,700



At 31 March 2026
12,020,700




Page 12

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

Subsidiary undertakings


The following were subsidiary undertakings of the Company:

Name

Class of shares

Holding

Willowbrook Healthcare Limited
Ordinary
100%
Willowbrook Healthcare Debtco Limited*
Ordinary
100%
Willowbrook Healthcare
Developments Limited*
Ordinary
100%
Avery Homes Rugeley Limited*
Ordinary
100%
Avery Homes Cliftonville Limited*
Ordinary
100%
Avery Homes Nuthall Limited*
Ordinary
100%
Avery Homes Moston Limited*
Ordinary
100%
Avery Homes Kirkstall Limited*
Ordinary
100%
Avery Homes Newcastle UL Limited*
Ordinary
100%
Avery Homes Nuneaton Limited*
Ordinary
100%
Avery Homes Wolverhampton Limited*
Ordinary
100%
Highcliffe Care Centre Limited*
Ordinary
100%
Avery Homes WSM Limited*
Ordinary
100%
Avery Homes Hanford Limited*
Ordinary
100%
Avery Homes Hatfield Limited*
Ordinary
100%
Avery Homes Weybridge Limited*
Ordinary
100%
Avery Homes Hinckley Limited*
Ordinary
100%
Avery Homes SH Limited*
Ordinary
100%
Avery Management Services Limited
Ordinary
100%
Avery Homes Derby Limited*
Ordinary
100%
Avery Homes TH Limited*
Ordinary
100%
Hawthorns Retirement Living Limited*
Ordinary
100%
Avery Homes (Nelson) Limited*
Ordinary
100%
Avery Homes RH Limited*
Ordinary
100%
Litchfield Care Limited*
Ordinary
100%
Avery Homes (Cannock) Limited
Ordinary
100%
Avery Healthcare Limited*
Ordinary
100%
Avery Healthcare Management Limited*
Ordinary
100%
Avery Homes Nominee 1 Limited*
Ordinary
100%
Avery Homes Nominee 2 Limited*
Ordinary
100%

* Indirect subsidiaries.
The registered address of the companies is 3 Cygnet Drive, Swan Valley, Northampton, NN4 9BS.


6.


Debtors

2026
2025
£
£

Amounts owed by group undertakings
4,094,647
4,094,647

Other debtors
2,631
2,631

4,097,278
4,097,278


Page 13

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

7.


Creditors: Amounts falling due within one year

2026
2025
£
£

Amounts owed to group undertakings
16,017,977
16,017,977

16,017,977
16,017,977



8.


Share capital

2026
2025
£
£
Allotted, called up and fully paid



1 (2025 - 1) Ordinary share of £1.00
1
1



9.


Reserves

Profit and loss account

"Profit and loss account" represents cumulative net gains and losses less distributions made.


10.Other financial commitments

The Company, together with a number of its fellow subsidiary undertakings, is part of a cross collateral security arrangement to secure the Group’s operating property leases with Welltower Inc of Toledo USA.


11.


Related party transactions

The Company has taken the exemption available in FRS 102 whereby it has not disclosed transactions with companies in the group where there is a direct or indirect 100% ownership.
Amounts owed by and to group undertakings are unsecured, interest free, have no fixed date of repayment and are repayable on demand.

Page 14

 
WILLOWBROOK HEALTHCARE GROUP LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

12.


Controlling party

At the year end, the Company was a subsidiary undertaking of Avery Healthcare Group Limited, a company incorporated in England and Wales. 
 
The largest UK group in which the results of the Company were consolidated were the group accounts of Veilchenblau Estates Limited, the Company’s ultimate UK parent company. The smallest group in which the results of the Company were consolidated were the group accounts of Avery Healthcare Holdings Limited, a company registered in England and Wales. The consolidated financial statements of both companies can be obtained from Companies House.
 
The ultimate parent company is Siena Enterprises Group Ltd, a company registered in the British Virgin Islands. 
The registered address of Avery Healthcare Holdings Limited is 3 Cygnet Drive, Swan Valley, Northampton, NN4 9BS.
The registered address for Veilchenblau Estates Limited is Millbank Tower, 21-24 Millbank, London SW1P 4QP.
The registered address for Siena Enterprises Group Ltd is 2nd Floor O'Neal Marketing Associates Building, PO Box 3174, Wickham's Cay II, Road Town, Tortola, British Virgin Islands.

Page 15